# Biobanking and Biovalidation Core

> **NIH NIH P20** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2024 · $246,588

## Abstract

ABSTRACT - Biobanking and Biomarker Validation (BBV) Core
The overall objective of the “Kansas Institute for Precision Medicine” (KIPM) COBRE Center at the University of
Kansas Medical Center (KUMC) is to advance the customization of healthcare through promoting innovative
scientific discoveries. We have entered the era of Precision Medicine, an initiative recently announced as part of
the 21st Century Cures Act, which is focused on using the molecular basis of diseases to better match patients
with the appropriate therapies and care resulting in improved outcomes. To advance this mission, we have
established the Biobanking and Biomarker Validation (BBV) Core, which combines exceptional expertise and
expands essential resources within established infrastructure, i.e., Biobanking - Biospecimen Repository Core
Facility (BRCF) and Biomarker Validation - Biomarker Discovery Laboratory (BDL). Access to the BBV core will
strengthen the biomedical research capacity of our COBRE Research Project Leaders (RPLs) and Pilot Project
Leaders (PPLs) by enhancing their research base and infrastructure capacities. To advance precision medicine
research within this Phase 2 COBRE program, the BBV core will 1) expand the services and infrastructure offered
by the BBV Core; 2) build a business strategy for the BBV Core that contributes to its long-term sustainability;
and 3) facilitate the competitiveness of KIPM COBRE RPLs and other faculty in securing external funding. The
BBV core is designed to centralize these essential services that will in turn provide support to the KIPM COBRE
faculty, pilot grantees, and researchers within our region and beyond. Given the level of sophistication of the
materials and services required for the range of studies proposed within the KIPM COBRE, a highly integrated
BBV core is not only cost effective but an absolute necessity. The BBV core eliminates redundant infrastructure
and expense required for each researcher to develop their own capabilities or to search for the necessary
research expertise. The BBV core will enable multiple COBRE RPLs and future pilot grantees, access to state-
of-the-art facilities and laboratory expertise, thereby further reducing the relative cost of their studies.
Furthermore, the BBV core will continue to provide in-kind technical staff-support and biobanking services, which
help the KIPM COBRE faculty to utilize their available funding more effectively, both institutional startup and
KIPM COBRE support. However, to remain sustainable the BBV Core will implement additional plans, including
an operational business strategy, to ensure its longevity persists. The success of the BBV core and ultimately
the COBRE faculty is essential to advancing the mission of the KIPM to advance the customization of healthcare
through promoting innovative scientific discoveries.

## Key facts

- **NIH application ID:** 10849363
- **Project number:** 2P20GM130423-06
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** ANDREW K. GODWIN
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $246,588
- **Award type:** 2
- **Project period:** 2019-02-15 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10849363

## Citation

> US National Institutes of Health, RePORTER application 10849363, Biobanking and Biovalidation Core (2P20GM130423-06). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10849363. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*